In this double-blind , randomized , placebo-controlled trial , @ patients with T@DM of @ @ years ' duration and an A@C of @ @ % ( @ @ mmol/mol ) completed @ weeks of IIT before randomization to daily subcutaneous liraglutide or placebo injection , with serial assessment of - cell function by Insulin Secretion-Sensitivity Index-@ ( ISSI-@ ) on oral glucose tolerance test performed every @ weeks .